NCT06144944 2026-01-30
Neoadjuvant Pyrotinib in HR-positive and HER2-low High-risk Early Breast Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 3 Active not recruiting
Clinical Trials
15 trialsNCT05910398 2025-11-18
CORINNE-PI
RenJi Hospital
Phase 3 Recruiting
NCT04254263 2025-09-11
ATP
RenJi Hospital
Phase 3 Recruiting
NCT03588091 2025-08-22
Neoadjuvant Study of Pyrotinib in Combination With Trastuzumab in Patients With HER2 Positive Breast Cancer
Jiangsu HengRui Medicine Co., Ltd.
Phase 3 Completed
NCT05424835 2025-08-22
A Trial of SHR-A1811versus Pyrotinib in Combination With Capecitabine in HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With Trastuzumab and Taxane
Jiangsu HengRui Medicine Co., Ltd.
Phase 3 Active not recruiting
NCT06278870 2024-02-26
Disitamab Vedotin + Pyrotinib Versus THP in the First-line Treatment for HER2+ Advanced Breast Cancer Clinical Trial
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 3 Recruiting
NCT05841381 2023-05-03
Adjuvant Study of Pyrotinib in Combination With Trastuzumab in HER2 Positive Invasive Breast Cancer
Fudan University
Phase 3 Not yet recruiting
NCT03863223 2022-11-23
A Study of Pyrotinib in Combination With Trastuzumab and Docetaxel in Patients With HER2 Metastatic Breast Cancer
Jiangsu HengRui Medicine Co., Ltd.
Phase 3 Unknown
NCT02973737 2022-10-25
A Study of Pyrotinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer
Jiangsu HengRui Medicine Co., Ltd.
Phase 3 Unknown
NCT05429684 2022-06-23
Precise Therapy for Refractory HER2 Positive Advanced Breast Cancer
First Affiliated Hospital Xi'an Jiaotong University
Phase 3 Unknown
NCT05346861 2022-04-26
Pyrotinib Rechallenge in Her2-positive Metastatic Breast Cancer Pretreated With Pyrotinib and Trastuzumab
Fudan University
Phase 3 Unknown
NCT04973319 2021-07-22
Trastuzumab Combined With Pertuzumab for Adjuvant Treatment of Breast Cancer After Neoadjuvant Therapy
Shengjing Hospital
Phase 3 Not yet recruiting
NCT03980054 2021-05-24
A Study of Evaluating The Effects Of Pyrotinib After Adjuvant Trastuzumab In Women With Early Stage Breast Cancer
Jiangsu HengRui Medicine Co., Ltd.
Phase 3 Unknown
NCT04646759 2020-11-30
Fulvestrant or Capecitabine Combined With Pyrotinib in HR+/HER2+ Metastatic Breast Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 3 Recruiting
NCT03080805 2020-06-18
Pyrotinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer. (PHOEBE)
Jiangsu HengRui Medicine Co., Ltd.
Phase 3 Unknown